

			TMENT OF COMMERCE D TRADEMARK OFFICE	Attorney Docket No.		50164/022002	
				Serial No.		10/617,424	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant		Alexis Borisy et al.	
				Filing Date		July 11, 2003	
				Group		1614	
(37 C.F.R. § 1.98(b))				IDS Filed		June 7, 2004	
				Customer No.		21559	
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)
YUU	5,770,593	06/23/98	Grunicke et al.				
رو)	6,569,853 B1	05/27/03	Borisy et al.				
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office		Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
14)	Lacey et al., "Activity of Benzimidazole Carbamates Against L1210 Mouse Leukaemia Cells: Correlation with In Vitro Tubulin Polymerization Assay," Biochemical Pharmacology 34:3603-3605 (1985), Abstract.						
	Makulu et al., "Effects of Pentamidine Upon Murine Leukemia and the Walker 256 Carcinoma (W256)," American Society for Pharmacology and Experimental Therapeutic," 16:105 (1974), Abstract.						
	Pourgholami et al., "In Vitro Inhibition of Human Liver Cancer Cells by Albendazole," Proceedings of the American Association for Cancer Research Annual Meeting 41:656 (2000), Abstract #4171.						
a	Ram et al., "Synthesis and Biological Activity of Certain Alkyl 5-(Alkoxycarbonyl)-1H-Benzimidazole-2-Carb-mates and Related Derivatives: A New Class of Potential Antineoplastic and Antifilarial Agents," Journal of Medicinal Chemistry and Pharmaceutical Chemistry 35:539-547 (1992), Abstract.						
EXAMINER 10 - (Iledoluja DATE CONSIDERED 12 7 - CT							
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							